Protagonist Therapeutics, Inc - Common Stock (PTGX)
CUSIP: 74366E102
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 62,457,444
- Total 13F shares
- 24,709
- Share change
- -2,167
- Total reported value
- $2,597,575
- Price per share
- $105.40
- Number of holders
- 13
- Value change
- -$181,096
- Number of buys
- 6
- Number of sells
- 4
Quarterly Holders Quick Answers
What is CUSIP 74366E102?
CUSIP 74366E102 identifies PTGX - Protagonist Therapeutics, Inc - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q4 2025
Recent filing periods for CUSIP 74366E102:
Top shareholders of PTGX - Protagonist Therapeutics, Inc - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
|
Company |
14%
from 13D/G
|
9,715,999
|
$848,595,367 | — | 31 Dec 2025 | |
| Farallon Capital Partners, L.P. |
13D/G
|
Dapice Joshua J. |
10%
|
6,248,013
|
$545,701,455 | +$25,461,794 | 31 Dec 2025 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
9.8%
|
6,144,006
|
$536,617,484 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
8.7%
|
5,413,690
|
$472,831,684 | — | 31 Dec 2025 | |
| RTW INVESTMENTS, LP |
13F
13D/G
|
Company |
8.1%
from 13D/G
|
5,059,053
|
$441,857,689 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
13D/G
|
Company · STATE STREET CORPORATION |
5.2%
from 13D/G
|
3,199,729
|
$279,464,331 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
13D/G
|
Company |
5.1%
from 13D/G
|
3,171,423
|
$276,992,086 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
4.4%
|
2,770,021
|
$241,933,634 | — | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
4.2%
|
2,649,981
|
$231,354,837 | — | 31 Dec 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
3.9%
|
2,449,183
|
$213,911,643 | — | 31 Dec 2025 | |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
|
BVF PARTNERS L P/IL |
4.1%
|
2,560,916
|
$170,121,650 | -$43,187,804 | 30 Sep 2025 | |
| Invesco Ltd. |
13F
|
Company |
2.5%
|
1,567,840
|
$136,935,146 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.3%
|
1,452,928
|
$126,919,578 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
2.3%
|
1,408,772
|
$123,042,146 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.2%
|
1,400,738
|
$122,341,000 | — | 31 Dec 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
2.2%
|
1,350,425
|
$117,946,120 | — | 31 Dec 2025 | |
| Deep Track Capital, LP |
13D/G
|
— |
2.8%
|
1,715,691
|
$113,973,353 | -$101,924,147 | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.8%
|
1,126,687
|
$98,404,842 | — | 31 Dec 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.8%
|
1,099,170
|
$96,001,508 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
1.7%
|
1,049,168
|
$91,634,333 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.6%
|
1,024,925
|
$89,516,950 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.5%
|
961,149
|
$83,946,754 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.4%
|
879,024
|
$76,774,142 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.4%
|
867,580
|
$75,774,437 | — | 31 Dec 2025 | |
| Ph.D. Dinesh V Patel |
3/4/5
|
President and CEO, Director |
0.84%
|
524,938
|
$53,018,738 | -$15,879,467 | 23 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.92%
|
575,118
|
$50,230,807 | — | 31 Dec 2025 | |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. |
13F
|
Company |
0.92%
|
571,825
|
$49,943,196 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.89%
|
556,762
|
$48,627,593 | — | 31 Dec 2025 | |
| FMR LLC |
13F
|
Company |
0.86%
|
539,878
|
$47,152,926 | — | 31 Dec 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.86%
|
535,423
|
$46,763,973 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.85%
|
529,631
|
$46,257,972 | — | 31 Dec 2025 | |
| Clearbridge Investments, LLC |
13F
|
Company |
0.78%
|
489,842
|
$42,782,833 | — | 31 Dec 2025 | |
| Commodore Capital LP |
13F
|
Company |
0.72%
|
450,000
|
$39,303,000 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.66%
|
414,415
|
$36,194,574 | — | 31 Dec 2025 | |
| 683 Capital Management, LLC |
13F
|
Company |
0.61%
|
380,669
|
$33,247,630 | — | 31 Dec 2025 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.59%
|
366,165
|
$31,980,852 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.56%
|
350,388
|
$30,602,888 | — | 31 Dec 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.56%
|
347,932
|
$30,388,381 | — | 31 Dec 2025 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
0.53%
|
331,164
|
$28,923,862 | — | 31 Dec 2025 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
0.53%
|
330,804
|
$28,893,000 | — | 31 Dec 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.37%
|
232,836
|
$20,335,896 | — | 31 Dec 2025 | |
| NEXTBio Capital Management LP |
13F
|
Company |
0.37%
|
229,619
|
$20,054,923 | — | 31 Dec 2025 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.35%
|
221,444
|
$19,340,919 | — | 31 Dec 2025 | |
| Holocene Advisors, LP |
13F
|
Company |
0.34%
|
210,019
|
$18,343,059 | — | 31 Dec 2025 | |
| Skandinaviska Enskilda Banken AB (publ) |
13F
|
Company |
0.33%
|
205,574
|
$17,954,833 | — | 31 Dec 2025 | |
| PUBLIC SECTOR PENSION INVESTMENT BOARD |
13F
|
Company |
0.33%
|
203,426
|
$17,767,227 | — | 31 Dec 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.32%
|
199,523
|
$17,426,339 | — | 31 Dec 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
0.32%
|
199,471
|
$17,421,797 | — | 31 Dec 2025 | |
| AIHC Capital Management Ltd |
13F
|
Company |
0.3%
|
189,823
|
$16,579,141 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.3%
|
187,642
|
$16,388,652 | — | 31 Dec 2025 |
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q1 2026
As of 31 Mar 2026,
Protagonist Therapeutics, Inc - Common Stock (PTGX) was held by
13 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,709 shares.
The largest 10 holders included
FRANKLIN STREET ADVISORS INC /NC, E Fund Management Co., Ltd., WEALTH ENHANCEMENT ADVISORY SERVICES, LLC, GAMMA Investing LLC, Farther Finance Advisors, LLC, SIGNATUREFD, LLC, E Fund Management (Hong Kong) Co., Ltd., MassMutual Private Wealth & Trust, FSB, Sankala Group LLC, and WOLFF WIESE MAGANA LLC.
This page lists
13
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
310
Q1 2026 holders
13
Holder diff
-297
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.